• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

深入研究基于α-酮酰胺的抑制剂与冠状病毒主蛋白酶的相互作用:一项详细的计算机模拟研究。

An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.

机构信息

Department of Chemistry, Government College of Engineering and Leather Technology, Salt Lake, Sector-3, Kolkata, PIN-700106, West Bengal, India.

出版信息

Biophys Chem. 2021 Feb;269:106510. doi: 10.1016/j.bpc.2020.106510. Epub 2020 Nov 28.

DOI:10.1016/j.bpc.2020.106510
PMID:33285430
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7695570/
Abstract

The search for therapeutic drugs that can neutralize the effects of COVID-2019 (SARS-CoV-2) infection is the main focus of current research. The coronavirus main protease (M) is an attractive target for anti-coronavirus drug design. Further, α-ketoamide is proved to be very effective as a reversible covalent-inhibitor against cysteine proteases. Herein, we report on the non-covalent to the covalent adduct formation mechanism of α-ketoamide-based inhibitor with the enzyme active site amino acids by QM/SQM model (QM = quantum mechanical, SQM = semi-empirical QM). To uncover the mechanism, we focused on two approaches: a concerted and a stepwise fashion. The concerted pathway proceeds via deprotonation of the thiol of cysteine (here, Cys SγH) and simultaneous reversible nucleophilic attack of sulfur onto the α-ketoamide warhead. In this work, we propose three plausible concerted pathways. On the contrary, in a traditional two-stage pathway, the first step is proton transfer from Cys SγH to His Nδ forming an ion pair, and consecutively, in the second step, the thiolate ion attacks the α-keto group to form a thiohemiketal. In this reaction, we find that the stability of the tetrahedral intermediate oxyanion/hydroxyl group plays an important role. Moreover, as the α-keto group has two faces Si or Re for the nucleophilic attack, we considered both possibilities of attack leading to S- and R-thiohemiketal. We computed the structural, electronic, and energetic parameters of all stationary points including transition states via ONIOM and pure DFT method. Additionally, to characterize covalent, weak noncovalent interaction (NCI) and hydrogen-bonds, we applied NCI-reduced density gradient (NCI-RDG) methods along with Bader's Quantum Theory of Atoms-in-Molecules (QTAIM) and natural bonding orbital (NBO) analysis.

摘要

寻找能够中和 COVID-19(SARS-CoV-2)感染效应的治疗性药物是当前研究的主要焦点。冠状病毒主蛋白酶(M)是抗冠状病毒药物设计的一个有吸引力的靶标。此外,α-酮酰胺已被证明是一种非常有效的半胱氨酸蛋白酶可逆共价抑制剂。在此,我们通过 QM/SQM 模型(QM=量子力学,SQM=半经验 QM)报告了基于α-酮酰胺的抑制剂与酶活性位点氨基酸的非共价到共价加合物形成机制。为了揭示机制,我们专注于两种方法:协同和逐步。协同途径通过半胱氨酸(此处为 Cys SγH)的硫醇去质子化和硫原子对α-酮酰胺弹头的同时可逆亲核攻击进行。在这项工作中,我们提出了三种可能的协同途径。相反,在传统的两步途径中,第一步是 Cys SγH 上的质子转移到 His Nδ 形成离子对,然后在第二步中,硫醇离子攻击α-酮基团形成硫代半缩酮。在这个反应中,我们发现四面体中间体氧阴离子/羟基的稳定性起着重要作用。此外,由于α-酮基团有两个面 Si 或 Re 可用于亲核攻击,我们考虑了两种可能的攻击方式,导致 S-和 R-硫代半缩酮。我们通过 ONIOM 和纯 DFT 方法计算了所有包括过渡态在内的稳定点的结构、电子和能量参数。此外,为了表征共价、弱非共价相互作用(NCI)和氢键,我们应用了 NCI 简化密度梯度(NCI-RDG)方法以及 Bader 的分子中的原子量子理论(QTAIM)和自然键轨道(NBO)分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/4998d77d63b4/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/add435883377/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/97789b298ed7/sc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/33e8c8516cec/sc2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/441d4fad0e83/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/f52b5239850a/sc3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/ef3b88ca0bfd/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/a775cb81683a/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/e795c3f8f193/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/58532c0d8bee/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/58d5d0526577/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/bbe4d627607e/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/93aa33d3b7ea/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/5aa0ccd87df4/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/4998d77d63b4/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/add435883377/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/97789b298ed7/sc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/33e8c8516cec/sc2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/441d4fad0e83/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/f52b5239850a/sc3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/ef3b88ca0bfd/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/a775cb81683a/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/e795c3f8f193/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/58532c0d8bee/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/58d5d0526577/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/bbe4d627607e/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/93aa33d3b7ea/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/5aa0ccd87df4/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/7695570/4998d77d63b4/gr10_lrg.jpg

相似文献

1
An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.深入研究基于α-酮酰胺的抑制剂与冠状病毒主蛋白酶的相互作用:一项详细的计算机模拟研究。
Biophys Chem. 2021 Feb;269:106510. doi: 10.1016/j.bpc.2020.106510. Epub 2020 Nov 28.
2
Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.针对 SARS-CoV-2 主蛋白酶的肽模拟抑制剂的共价和非共价结合自由能计算。
Phys Chem Chem Phys. 2021 Mar 21;23(11):6746-6757. doi: 10.1039/d1cp00266j. Epub 2021 Mar 12.
3
Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of α-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2.探索共价抑制机制:模拟 SARS-CoV-2 主蛋白酶的 α-酮酰胺抑制剂的结合自由能。
Biochemistry. 2020 Dec 8;59(48):4601-4608. doi: 10.1021/acs.biochem.0c00782. Epub 2020 Nov 18.
4
QM/QM studies for Michael reaction in coronavirus main protease (3CL Pro).冠状病毒主要蛋白酶(3CL Pro)中迈克尔反应的量子力学/量子力学研究
J Mol Graph Model. 2008 Oct;27(3):275-85. doi: 10.1016/j.jmgm.2008.05.002. Epub 2008 May 9.
5
Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs*.多尺度模拟揭示酮类抑制剂对 SARS-CoV-2 主蛋白酶的抑制机制:改进设计的见解*。
Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25933-25941. doi: 10.1002/anie.202110027. Epub 2021 Nov 3.
6
Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2.针对 SARS-CoV-2 主蛋白酶的半胱氨酸靶向共价抑制剂。
J Biomol Struct Dyn. 2022 Mar;40(4):1639-1658. doi: 10.1080/07391102.2020.1831610. Epub 2020 Oct 13.
7
Tuning Proton Transfer Thermodynamics in SARS-CoV-2 Main Protease: Implications for Catalysis and Inhibitor Design.调控 SARS-CoV-2 主蛋白酶的质子转移热力学:对催化和抑制剂设计的影响。
J Phys Chem Lett. 2021 May 6;12(17):4195-4202. doi: 10.1021/acs.jpclett.1c00425. Epub 2021 Apr 26.
8
Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.利用美国食品和药物管理局批准的伊曲康唑(一种 P2-P3α-酮酰胺衍生物)和戊谷胺靶向 SARS-CoV-2 主蛋白酶:一种基于计算机的药物发现方法。
J Mol Graph Model. 2020 Dec;101:107730. doi: 10.1016/j.jmgm.2020.107730. Epub 2020 Sep 2.
9
Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.基于配体/基于结构的虚拟筛选、分子动力学模拟和结合能计算发现 SARS-CoV-2 主要蛋白酶的有效抑制剂。
Phys Chem Chem Phys. 2020 Oct 21;22(40):23099-23106. doi: 10.1039/d0cp04326e.
10
Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.基于结构的中草药芦丁抑制 SARS-CoV-2 主蛋白酶的先导优化。
Phys Chem Chem Phys. 2020 Nov 21;22(43):25335-25343. doi: 10.1039/d0cp03867a. Epub 2020 Nov 3.

引用本文的文献

1
Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.探索新型冠状病毒主要蛋白酶的共价抑制剂:从拟肽到新型骨架
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2460045. doi: 10.1080/14756366.2025.2460045. Epub 2025 Feb 6.
2
Targeting SARS-CoV-2 Non-Structural Proteins.靶向 SARS-CoV-2 非结构蛋白。
Int J Mol Sci. 2023 Aug 20;24(16):13002. doi: 10.3390/ijms241613002.
3
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.

本文引用的文献

1
Mechanism of inhibition of SARS-CoV-2 M by peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity.通过量子力学/分子力学模拟解释肽基迈克尔受体对SARS-CoV-2 M的抑制机制以及设计具有可调化学反应性的新衍生物
Chem Sci. 2020 Nov 27;12(4):1433-1444. doi: 10.1039/d0sc06195f.
2
A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design.SARS-CoV-2主要蛋白酶受迈克尔受体抑制作用的微观描述。改进抑制剂设计的策略。
Chem Sci. 2021 Jan 29;12(10):3489-3496. doi: 10.1039/d0sc04978f.
3
Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 M by QM/MM computational methods.
靶向 SARS-CoV-2 主蛋白酶治疗 COVID-19:共价抑制剂结构-活性关系的洞察和进化视角。
J Med Chem. 2022 Oct 13;65(19):12500-12534. doi: 10.1021/acs.jmedchem.2c01005. Epub 2022 Sep 28.
4
Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease.丙型肝炎病毒 NS3/4A 抑制剂和其他类似药物化合物作为 SARS-CoV-2 主蛋白酶的共价结合物。
Sci Rep. 2022 Jul 16;12(1):12197. doi: 10.1038/s41598-022-15930-z.
5
Effect of pH on stability of dimer structure of the main protease of coronavirus-2.pH 值对冠状病毒主蛋白酶二聚体结构稳定性的影响。
Biophys Chem. 2022 Aug;287:106829. doi: 10.1016/j.bpc.2022.106829. Epub 2022 May 19.
通过量子力学/分子力学计算方法揭示新冠病毒M蛋白的蛋白水解分子机制。
Chem Sci. 2020 Jun 25;11(39):10626-10630. doi: 10.1039/d0sc02823a.
4
Tuning Proton Transfer Thermodynamics in SARS-CoV-2 Main Protease: Implications for Catalysis and Inhibitor Design.调控 SARS-CoV-2 主蛋白酶的质子转移热力学:对催化和抑制剂设计的影响。
J Phys Chem Lett. 2021 May 6;12(17):4195-4202. doi: 10.1021/acs.jpclett.1c00425. Epub 2021 Apr 26.
5
How the Destabilization of a Reaction Intermediate Affects Enzymatic Efficiency: The Case of Human Transketolase.反应中间体的不稳定如何影响酶的效率:以人转酮醇酶为例。
ACS Catal. 2020 Feb 21;10(4):2872-2881. doi: 10.1021/acscatal.9b04690. Epub 2020 Feb 7.
6
Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.通过分子对接、分子动力学模拟和自由能计算对 COVID-19 主蛋白酶抑制剂的合理方法。
Sci Rep. 2020 Oct 19;10(1):17716. doi: 10.1038/s41598-020-74468-0.
7
Structural plasticity of SARS-CoV-2 3CL M active site cavity revealed by room temperature X-ray crystallography.室温 X 射线晶体学揭示 SARS-CoV-2 3CL M 活性位点腔的结构可塑性。
Nat Commun. 2020 Jun 24;11(1):3202. doi: 10.1038/s41467-020-16954-7.
8
Critical Differences between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.新冠病毒和非典病毒刺突蛋白结合特征的关键差异。
J Phys Chem B. 2020 Jul 16;124(28):5907-5912. doi: 10.1021/acs.jpcb.0c04317. Epub 2020 Jul 6.
9
Interaction of the prototypical α-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.在计算机模拟中,典型α-酮酰胺抑制剂与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶活性位点的相互作用:分子动力学模拟突出了配体-蛋白质复合物的稳定性。
Comput Biol Chem. 2020 May 28;87:107292. doi: 10.1016/j.compbiolchem.2020.107292.
10
Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.针对可能抑制新型冠状病毒主要蛋白酶的临床导向药物的分子机制探索
J Phys Chem Lett. 2020 Jun 4;11(11):4413-4420. doi: 10.1021/acs.jpclett.0c00994. Epub 2020 May 21.